CION Ameerpet
Immunotherapy · When It Stops Working & Difficult Decisions
Why Does Immunotherapy Stop Working — Acquired Resistance Explained
It worked. The scans were better, or at least steady, and now they are not. That is called acquired resistance, and it is a change in the cancer and in the immune cells around it — not the drug wearing off, and not anything you or your family did wrong.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- The cancer changed, not the drug — Checkpoint inhibitors do not lose potency; the tumour and the immune cells around it adapt.
- It was not caused by anything you did — Not diet, not stress, not a moved cycle. No test predicts it in advance either.
- The pattern on the scan matters — One growing deposit with the rest controlled is a different problem from several sites at once.
- Options usually remain — Confirm the progression, treat one site locally, switch class, ask about a trial, or focus on symptoms.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The short answer
What Does It Mean When Immunotherapy Stops Working?
It means the treatment worked for a period and the cancer has found a way around it. Doctors call this acquired resistance. The immune response that was holding the disease has been escaped, blocked or exhausted. It is a change in the cancer and in the immune system around it, not the drug losing strength or your body getting used to it.
The name for it is acquired resistance. It describes a cancer that responded to a checkpoint inhibitor and then found a way around it. That is a different situation from primary resistance, where the cancer never responded at any point, and the two lead to different conversations about what to do next.
It is not the same as the drug wearing off. Checkpoint inhibitors do not lose potency the way a painkiller does. The dose has not become too small and your body has not become used to it. What has changed is the cancer, or the immune cells that were controlling it, or the environment immediately around the tumour.
One growing spot is not automatically the whole picture. Sometimes the entire disease starts progressing. Sometimes a single deposit grows while everything else stays controlled, which is a different pattern with different options. Ask your oncologist which of these the scan actually shows, because families are often told progression and assume the worst version of it.
The first task is to confirm it is real. Growth on one scan is not always confirmed growth, which is why a repeat scan after a short interval is sometimes arranged before any decision is taken. Response-assessment imaging is coordinated at partner imaging centres, so ask that your earlier images travel with the new ones for direct comparison.
What is happening underneath
Why Does a Treatment That Was Working Stop Working?
Because the cancer and the immune system both keep changing. Tumour cells can stop displaying the markers that immune cells recognise. They can stop responding to immune signals. The T cells doing the work can become exhausted. Other brakes can come up in place of the one being blocked. Usually several of these are happening at once.
The cancer can stop showing itself. Immune cells recognise a tumour by abnormal proteins displayed on the surface of its cells. Tumour cells that lose those markers, or that lose the display machinery itself, become effectively invisible to a system that is still working perfectly well.
The cancer can stop listening to the immune signal. When immune cells attack, they release signals that ordinarily damage the tumour and make it more visible. Tumour cells that acquire faults in the pathways that receive those signals no longer respond to them.
The immune cells themselves can run out. T cells that have been fighting continuously for months become progressively less functional. Releasing one brake does not help a cell that has lost its capacity to act.
The cancer can put up a different brake. A checkpoint inhibitor blocks one specific brake. Other inhibitory molecules can be brought up in its place, and the surrounding tissue can recruit cells whose job is to damp immune activity down.
Sometimes a resistant population was always there. A tumour is not one uniform thing. A small group of cells that never displayed the markers can survive while the rest is cleared, and over months that group becomes the disease you can see on the scan.
These mechanisms are described in the immuno-oncology literature and summarised in ESMO and ASCO educational material. They are not competing theories. In a given patient, several are usually operating together, and it is rarely possible to say which one applies to you.
Did you know?
Acquired resistance is not caused by anything the patient did or failed to do. It is not a consequence of diet, of stress, of a missed cycle or of a scan that ran late. It is a biological change in the tumour and in the immune cells around it. Families carry a great deal of guilt at this point, and almost all of it is misplaced — the useful question is what the pattern on this scan opens up, not what somebody should have done differently.
Read the scan before the prognosis
Does the Pattern on the Scan Change What Happens Next?
Yes, a great deal. One growing deposit with everything else controlled is a different problem from several sites growing at once. The first often opens the option of treating that single site locally while the systemic treatment continues. Ask your oncologist which of these the scan shows, in those words.
This is a general map to help you follow the conversation. It is not a rule that decides your case, and only your own team can read your scan against your history.
| What the scan shows | What it usually suggests | The conversation it usually opens |
|---|---|---|
| One deposit growing, the rest controlled | Localised escape rather than whole-disease resistance. | Whether that single site can be treated locally while the systemic treatment continues. |
| Several sites growing together | A broader loss of control across the disease. | Whether to switch to a different class of treatment, look at a trial, or move the emphasis to symptom control. |
| A new deposit in a new organ | New disease that the current treatment is not reaching, which is a different problem in the brain from elsewhere. | Whether local treatment to the new site is needed, and whether the systemic plan changes as well. |
| Growth that is borderline or unclear | It may not be confirmed progression at all. | Whether to repeat imaging after a short interval before changing anything. |
| Growth on the scan while you feel well | Radiological change without clinical change. | Whether continuing the current treatment under close review is reasonable while the picture is confirmed. |
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Told the Immunotherapy Has Stopped Working?
A medical oncologist can compare the scan directly against the baseline images, explain what the pattern means, and lay out every option that remains, including the ones you may not have been offered.
A framework, not a recommendation
Can Acquired Resistance Be Overcome?
Sometimes, and the honest answer is that reversing it reliably is not yet possible. What can often be done is to work around it: confirm the progression is real, treat a single escaping site locally, switch to a different class of treatment, or look at a trial. Which of these applies depends on the pattern and on how well you are.
These are options to ask about, not a ranking. Combinations that block a second checkpoint alongside PD-1 are approved in some countries for particular cancers; whether any such combination is available and appropriate in India is a question for your own oncologist, and the status should be checked rather than assumed.
| Option | What it involves | Who typically considers it |
|---|---|---|
| Confirm the progression first | A repeat scan after a short interval, with the earlier images available for direct comparison, before anything is changed. | Patients who feel well, where the growth on the scan is limited or borderline. |
| Treat one site locally, continue the rest | Radiotherapy, surgery or another local treatment aimed at the single growing deposit, with a radiation oncologist involved in the decision. | Patients where one area is escaping while the remainder of the disease stays controlled. |
| Continue the same treatment beyond progression | Carrying on under close review, with an agreed point at which the decision is revisited. | Selected patients who remain clinically stable and well, where the alternative is not clearly better. |
| Switch to a different class of treatment | Chemotherapy, a targeted therapy where a driver mutation exists, or another approved agent for your cancer type. | Patients well enough for further disease-directed treatment where an option has not yet been used. |
| Ask about a clinical trial | An investigational treatment under a study protocol. Criteria are strict, a place is never promised, and no benefit can be claimed in advance. | Patients looking beyond approved treatment who remain fit enough to meet trial criteria. |
| Symptom control without further anti-cancer treatment | Pain, breathlessness, appetite and fatigue managed actively, with no treatment aimed at the cancer itself. | Patients and families prioritising comfort, time at home and fewer hospital visits. |
The question families ask last, and mean most
Was It Inevitable, and Did We Miss Something?
Nothing you did caused this. Not the diet, not the fasting, not the wedding you went to, not the stress at home. The mechanisms behind acquired resistance are changes in tumour cells and in immune cells. They are not responsive to the things families spend months blaming themselves for.
No test predicts it in advance. There is no scan, no blood test and no biomarker that reliably tells anyone at the start of treatment whether or when a response will be escaped. If there had been, it would have been done. An oncologist who says nobody can predict this is describing where the evidence sits, not avoiding your question.
A late scan or a shifted cycle is rarely the explanation. Cycles get moved for infections, for blood results, for festivals and for scanner availability, and that is normal care rather than negligence. If a specific delay is troubling you, put it to your oncologist directly and ask whether it made a difference. Carrying it silently for months is worse than asking once.
What is worth asking is different from what is worth blaming. Ask whether all relevant biomarkers were tested, whether anything was left untested for want of tissue, whether a repeat biopsy would change the plan, and what the goal of any next treatment would be. Those questions can change a decision. The blame question cannot.
Understanding the mechanism helps more than it looks as though it will. Families who understand that the cancer changed, rather than that the patient failed the treatment or the treatment failed the patient, tend to make the next set of decisions more calmly and with less quarrelling among themselves. That is the honest reason this page explains the biology at all.
A parallel service, not a last resort
Does This Mean Moving to Palliative Care?
No, not on its own, and palliative care is not the alternative to treatment in any case. It is symptom and quality-of-life support that runs alongside cancer treatment. You can start a different systemic treatment and see a palliative care team in the same week. ASCO and WHO both describe it as a service to introduce early.
In practice, a palliative care team works on the parts of the illness a busy oncology clinic has the least time for: pain that is not fully controlled, breathlessness, appetite, sleep, anxiety in both patient and family, and practical planning. Adding them does not remove your oncologist, does not cancel your next scan, and does not change your eligibility for a further line of treatment.
It also does not commit you to a decision. Many families find that having symptoms properly controlled is what finally makes a clear-headed conversation about goals of care possible, because nobody is trying to decide anything while in pain or unable to sleep. Ask for the referral early rather than at the point where it becomes urgent.
Progression is a decision point, not the end of the options
Take the Next Decision With the Full Picture
A free second opinion gives you confirmation of what the scan shows, the testing gaps, the realistic options and an honest goals-of-care conversation.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Acquired Resistance to Immunotherapy — Your Questions Answered
What does acquired resistance to immunotherapy mean?
It means the treatment worked for a period and the cancer has since found a way around it. Doctors separate this from primary resistance, where the cancer never responded at any point, because the two lead to different decisions. Acquired resistance is not the drug wearing off or your body becoming used to it. Checkpoint inhibitors do not lose potency in that way. What has changed is the cancer, the immune cells that were controlling it, or the tissue immediately around the tumour. The first thing your oncologist will want to establish is whether the growth on the scan is confirmed, and whether it is one site or the whole disease.
Why does immunotherapy stop working after it worked at first?
Because both the cancer and the immune system keep changing. Tumour cells can stop displaying the abnormal proteins that immune cells recognise, or lose the machinery that displays them, which makes them effectively invisible. They can acquire faults that stop them responding to the signals immune cells release. The T cells doing the work can become exhausted after months of continuous activity. Other inhibitory molecules can come up in place of the one being blocked. And a small population of resistant cells may have been present all along and simply outlasted the rest. These mechanisms are described in the immuno-oncology literature and summarised in ESMO and ASCO educational material, and in most patients several are operating together.
Was it something we did wrong, or something that was missed?
Almost certainly neither. Acquired resistance is a biological change in tumour cells and in the immune cells around them. It is not caused by diet, by stress, by attending a function, or by a cycle that was moved. No scan, blood test or biomarker reliably predicts in advance whether or when a response will be escaped, so nothing could have been watched for that was not. Cycles are shifted routinely for infections, blood results and scanner availability, and that is normal care. If a specific delay is weighing on you, put it to your oncologist directly and ask whether it made a difference, rather than carrying it silently for months.
Can acquired resistance be reversed or overcome?
Reversing it reliably is not yet possible, and any page that suggests otherwise is overstating what is known. What can often be done is to work around it. The options usually discussed are: confirming the progression is real with a repeat scan before anything changes; treating a single escaping site locally with radiotherapy or surgery while the systemic treatment continues; continuing the same treatment under close review in selected patients who remain well; switching to a different class of treatment such as chemotherapy or a targeted therapy where a driver mutation exists; asking whether a clinical trial exists that you might be eligible for; or focusing on symptom control without further treatment aimed at the cancer. Which of these applies depends on your cancer type, the pattern on the scan and how well you are.
Does one growing spot mean the whole treatment has failed?
Not necessarily, and this is worth asking about in exactly those words. One deposit growing while everything else stays controlled is a recognised pattern and is a different problem from several sites progressing together. It often opens the option of treating that one site locally, with a radiation oncologist involved, while the systemic treatment carries on. Families are frequently told the word progression and reasonably assume the worst version of it. Ask your oncologist whether every site grew or only some, and whether the new images were compared directly against the baseline scan rather than against the report of the last one.
Does immunotherapy stopping mean moving to palliative care?
No. Palliative care is symptom and quality-of-life support that runs alongside cancer treatment, not after it, and both ASCO and WHO describe it as a service to introduce early rather than reserve for the final weeks. You can start a different systemic treatment and see a palliative care team in the same week. In practice that team covers pain, breathlessness, appetite, sleep, anxiety, family support and practical planning, which are the parts of the illness a busy oncology clinic has least time for. Asking for it does not remove your oncologist, does not cancel your next scan, and does not signal that you have stopped considering treatment.
This page is general patient-education information, not a substitute for the written guidance your own oncology team gives you based on your specific diagnosis, scans and treatment history.